Key result
Castor stents linked to ~7-point fewer midterm stent complications versus in situ fenestration.
Why the study?
To evaluate the midterm efficacy of the Castor stent versus in situ fenestration for reconstructing the left subclavian artery in patients with type B aortic dissection.
Does Castor stent implantation reduce stent-related complications and reintervention compared to the in situ fenestration stent technique in patients with type B aortic dissection involving the left subclavian artery?
Cohort (n=247)
No
Does Castor stent implantation reduce stent-related complications and reintervention compared to the in situ fenestration stent technique in patients with type B aortic dissection involving the left subclavian artery?
In patients with type B aortic dissection involving the left subclavian artery undergoing TEVAR, Castor branched stents significantly reduced operative/fluoroscopy times, midterm stent-related complications, and need for reintervention compared to in situ fenestration.
Answers are grounded in this paper and cite their sources.
Castor stents were associated with fewer complications in this cohort; leaves open whether they should replace in situ fenestration.
To evaluate the midterm efficacy of the Castor stent (CS) versus in situ fenestration (ISF) for reconstructing the left subclavian artery (LSA) in patients with type B aortic dissection (TBAD). Between July 2017 and July 2022, a total of 247 patients with TBAD were enrolled. One hundred thirty-seven patients were treated using CSs (group A), while the remaining 110 patients received ISFs (group B). Data of the two groups were retrospectively analyzed. The success rates of surgery were 99.3% and 95.5% in groups A and B (p = .053), There were no deaths during hospitalization. During surgery, group B showed a longer surgical duration [68.0 (66.0, 77.0) vs. 62.0 (59.0, 66.0) min, p < .001] and intraoperative fluoroscopy time [18.0 (16.0, 20.0) vs. 16.0 (14.0, 18.0) min, p < .001] than group A. The follow-up duration was similar for both groups (44.0 vs. 43.0 months, p = .877), and no patient died. Stent-related complications were significantly lower in group A than in group B (1.5% vs. 8.4%, p = .009). Group A had fewer instances entry flow (0.7% vs. 4.7%, p = .048) and stent stenosis (0.7% vs. 2.8%, p = .206) than group B. All reintervention cases (4.7%) were from group B (p = .011). The rate of false aortic lumen thrombosis was significantly higher in group A than in group B (84.6% vs. 72.9%, p = .024). Both CSs and ISFs are evidently safe, feasible, and effective in achieving positive early outcomes in patients undergoing treatment for TBAD. Notably, at midterm follow-up, CSs appeared to be superior to ISF in terms of reducing stent-related complications and minimizing the need for reintervention.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2023) conducted a cohort in Type B aortic dissection (TBAD) involving the left subclavian artery (LSA) (n=247). Castor stent (CS) implantation vs. In situ fenestration (ISF) stent implantation was evaluated on Midterm stent-related complications (entry flow, stent migration, stent stenosis, stent occlusion, and mediastinal infection) (p=0.009). Castor stents reduced midterm stent-related complications compared to in situ fenestration and lowered reintervention rates.
Synapse has enriched 10 related papers. Consider them for comparative context: